Phase III
Shares of Aprea Therapeutics plunged more than 77% in morning trading after the company announced its late-stage cancer combination treatment failed to meet its primary endpoint of complete remission rate.
Even with the holidays among us, there were a number of clinical trial announcements. Here’s a look.
As a result, the company has decided to unblind the treatment assignments of patients in the trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
Rhythm Pharmaceuticals announced on Tuesday that its hunger and severe obesity drug, setmelanotide, significantly reduced weight and hunger scores in people with Bardet-Biedl syndrome and Alström syndrome.
An investigational asthma treatment, tezepelumab, under development by Amgen and AstraZeneca failed to reduce asthma patients’ dependence on corticosteroids.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
The FDA put a clinical hold on UniQure’s Phase III trial after a high-risk participant developed liver cancer.
Genentech, a Roche company, announced positive topline data from two identical Phase III trials of faricimab in diabetic macular edema (DME).
A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with placebo.
PRESS RELEASES